A short-course of Soliris (eculizumab) treatment during relapses may help people with neuromyelitis optica spectrum disorder (NMOSD) recover faster when standard therapies fail, a small study in China suggests. Patients who saw little or no improvement after corticosteroids, with or without plasma exchange, experienced meaningful gains in mobility…
mobility
My quest to become a wheelchair owner and user began with pitching the idea to members of my care team. As I shared in my last column, that didn’t go as smoothly as I’d hoped. But being persistent paid off when one of my doctors stepped up and…
Recent Posts
- NMOSD treatment linked to fewer relapses in real-world study
- I may be a caregiver, but I’m not my wife’s hero; I’m her husband
- Early trial of experimental CAR T-cell therapy seeks people with NMOSD
- Because patients are the reason for the research, we deserve a seat at the table
- Disability in NMOSD patients may worsen even without relapses